INmune Bio Inc.
INMB
$2.17
$0.094.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | 257.14% | 19.05% | -41.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | 257.14% | 19.05% | -41.18% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -100.00% | 257.14% | 19.05% | -41.18% |
| SG&A Expenses | 13.87% | 6.81% | 8.10% | -5.77% | -12.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.21% | -35.59% | -27.50% | -16.05% | 4.99% |
| Operating Income | 49.15% | 35.52% | 27.60% | 16.09% | -5.10% |
| Income Before Tax | 66.82% | -1.97% | -9.15% | -20.87% | -47.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 66.82% | -1.97% | -9.15% | -20.87% | -47.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.82% | -1.97% | -9.15% | -20.87% | -47.07% |
| EBIT | 49.15% | 35.52% | 27.60% | 16.09% | -5.10% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 72.27% | 13.16% | 9.67% | 1.90% | -21.27% |
| Normalized Basic EPS | 59.99% | 48.32% | 41.88% | 33.35% | 13.17% |
| EPS Diluted | 72.27% | 13.16% | 9.67% | 1.90% | -21.27% |
| Normalized Diluted EPS | 59.99% | 48.32% | 41.88% | 33.35% | 13.17% |
| Average Basic Shares Outstanding | 20.70% | 22.36% | 24.09% | 25.26% | 20.26% |
| Average Diluted Shares Outstanding | 20.70% | 22.36% | 24.09% | 25.26% | 20.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |